These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 12215566

  • 1. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.
    Shen S, Meredith RF, Duan J, Macey DJ, Khazaeli MB, Robert F, LoBuglio AF.
    J Nucl Med; 2002 Sep; 43(9):1245-53. PubMed ID: 12215566
    [Abstract] [Full Text] [Related]

  • 2. Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy.
    Shen S, Meredith RF, Duan J, Brezovich I, Khazaeli MB, LoBuglio AF.
    Cancer Biother Radiopharm; 2003 Apr; 18(2):209-15. PubMed ID: 12804046
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
    Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens PC, Snow GB, van Dongen GA.
    J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
    [Abstract] [Full Text] [Related]

  • 7. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody.
    Breitz HB, Fisher DR, Wessels BW.
    J Nucl Med; 1998 Oct; 39(10):1746-51. PubMed ID: 9776281
    [Abstract] [Full Text] [Related]

  • 8. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
    Behr TM, Sgouros G, Stabin MG, Béhé M, Angerstein C, Blumenthal RD, Apostolidis C, Molinet R, Sharkey RM, Koch L, Goldenberg DM, Becker W.
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
    [Abstract] [Full Text] [Related]

  • 9. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
    Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, Nanus DM, Bander NH.
    J Nucl Med; 2005 May; 46(5):850-8. PubMed ID: 15872360
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
    Elgqvist J, Andersson H, Bäck T, Claesson I, Hultborn R, Jensen H, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L.
    Nucl Med Biol; 2006 Nov; 33(8):1065-72. PubMed ID: 17127181
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
    Shen S, Forero A, LoBuglio AF, Breitz H, Khazaeli MB, Fisher DR, Wang W, Meredith RF.
    J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
    [Abstract] [Full Text] [Related]

  • 15. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings.
    Behr TM, Béhé M, Sgouros G.
    Cancer Biother Radiopharm; 2002 Aug; 17(4):445-64. PubMed ID: 12396708
    [Abstract] [Full Text] [Related]

  • 16. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.
    Ferrer L, Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Le Gouill S, Wegener WA, Goldenberg DM, Bardiès M.
    Cancer; 2010 Feb 15; 116(4 Suppl):1093-100. PubMed ID: 20127958
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ.
    J Nucl Med; 2003 Oct 15; 44(10):1690-9. PubMed ID: 14530488
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.